Search

Your search keyword '"Schepisi, Giuseppe"' showing total 252 results
Start Over Author "Schepisi, Giuseppe"
252 results on '"Schepisi, Giuseppe"'

3. Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study

Author

Casadei, Chiara, Scarpi, Emanuela, Conteduca, Vincenza, Gurioli, Giorgia, Cursano, Maria Concetta, Brighi, Nicole, Lolli, Cristian, Schepisi, Giuseppe, Basso, Umberto, Fornarini, Giuseppe, Bleve, Sara, Farolfi, Alberto, Altavilla, Amelia, Burgio, Salvatore Luca, Giunta, Emilio Francesco, Gianni, Caterina, Filograna, Alessia, Ulivi, Paola, Olmos, David, Castro, Elena, and De Giorgi, Ugo

Published
2024
Full Text
View/download PDF

4. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.

Author

Giunta, Emilio Francesco, Caroli, Paola, Scarpi, Emanuela, Altavilla, Amelia, Rossetti, Virginia, Marini, Irene, Celli, Monica, Casadei, Chiara, Lolli, Cristian, Schepisi, Giuseppe, Bleve, Sara, Brighi, Nicole, Cursano, Maria Concetta, Paganelli, Giovanni, Matteucci, Federica, and De Giorgi, Ugo

Subjects
CASTRATION-resistant prostate cancer, PROSTATE cancer patients, PROSTATE-specific antigen, SURVIVAL analysis (Biometry), PROSTATE cancer
Abstract

Purpose: to assess the utility of response monitoring to enzalutamide by using [68Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy. Methods: patients underwent [68Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method. Results: 69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones. Conclusions: [68Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. 68Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study.

Author

Giunta, Emilio Francesco, primary, Caroli, Paola, additional, Scarpi, Emanuela, additional, Altavilla, Amelia, additional, Marini, Irene, additional, Celli, Monica, additional, Casadei, Chiara, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Bleve, Sara, additional, Brighi, Nicole, additional, Cursano, Maria Concetta, additional, Martinelli, Giovanni, additional, Matteucci, Federica, additional, and De Giorgi, Ugo, additional

Published
2024
Full Text
View/download PDF

7. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Author

Caffo, Orazio, Ortega, Cinzia, Nolè, Franco, Gasparro, Donatello, Mucciarini, Claudia, Aieta, Michele, Zagonel, Vittorina, Iacovelli, Roberto, De Giorgi, Ugo, Facchini, Gaetano, Veccia, Antonello, Palesandro, Erica, Verri, Elena, Buti, Sebastiano, Razzini, Giorgia, Bozza, Giovanni, Maruzzo, Marco, Ciccarese, Chiara, Schepisi, Giuseppe, Rossetti, Sabrina, Maines, Francesca, Kinspergher, Stefania, Fratino, Lucia, Ermacora, Paola, Nicodemo, Maurizio, Giordano, Monica, Sartori, Donata, Scapoli, Daniela, Sabbatini, Roberto, Lo Re, Giovanni, Morelli, Franco, D’Angelo, Alessandro, Vittimberga, Isabella, Lippe, Paolo, Carrozza, Francesco, Messina, Caterina, Galli, Luca, Valcamonico, Francesca, Porta, Camillo, Pappagallo, Giovanni, and Aglietta, Massimo

Published
2021
Full Text
View/download PDF

8. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study

Author

Conteduca, Vincenza, Wetterskog, Daniel, Castro, Elena, Scarpi, Emanuela, Romero-Laorden, Nuria, Gurioli, Giorgia, Jayaram, Anuradha, Lolli, Cristian, Schepisi, Giuseppe, Wingate, Anna, Casadei, Chiara, Lozano, Rebeca, Brighi, Nicole, Aragón, Isabel M., Marin-Aguilera, Mercedes, Gonzalez-Billalabeitia, Enrique, Mellado, Begoña, Olmos, David, Attard, Gerhardt, and De Giorgi, Ugo

Published
2021
Full Text
View/download PDF

12. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer

Author

Conteduca, Vincenza, Wetterskog, Daniel, Scarpi, Emanuela, Romanel, Alessandro, Gurioli, Giorgia, Jayaram, Anuradha, Lolli, Cristian, Tandefelt, Delila Gasi, Schepisi, Giuseppe, Casadei, Chiara, Wingate, Anna, Matteucci, Federica, Paganelli, Giovanni, Gonzalez-Billalabeitia, Enrique, Demichelis, Francesca, De Giorgi, Ugo, and Attard, Gerhardt

Published
2020
Full Text
View/download PDF

13. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

Author

Conteduca, Vincenza, Castro, Elena, Wetterskog, Daniel, Scarpi, Emanuela, Jayaram, Anuradha, Romero-Laorden, Nuria, Olmos, David, Gurioli, Giorgia, Lolli, Cristian, Sáez, Maria Isabel, Puente, Javier, Schepisi, Giuseppe, Salvi, Samanta, Wingate, Anna, Medina, Ana, Querol-Niñerola, Rosa, Marin-Aguilera, Mercedes, Arranz, Jose Angel, Fornarini, Giuseppe, Basso, Umberto, Mellado, Begoña, Gonzalez-Billalabeitia, Enrique, Attard, Gerhardt, and De Giorgi, Ugo

Published
2019
Full Text
View/download PDF

15. Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Author

Farolfi, Alberto, primary, Petracci, Elisabetta, additional, Gurioli, Giorgia, additional, Tedaldi, Gianluca, additional, Casanova, Claudia, additional, Arcangeli, Valentina, additional, Amadori, Andrea, additional, Rosati, Marta, additional, Stefanetti, Marco, additional, Burgio, Salvatore Luca, additional, Cursano, Maria Concetta, additional, Lolli, Cristian, additional, Zampiga, Valentina, additional, Cangini, Ilaria, additional, Schepisi, Giuseppe, additional, and De Giorgi, Ugo, additional

Published
2023
Full Text
View/download PDF

20. Inherited mutations in DNA damage gene repair (gDDR) in Italian men with metastatic prostate cancer.

Author

De Giorgi, Ugo, primary, Casadei, Chiara, additional, Conteduca, Vincenza, additional, Gurioli, Giorgia, additional, Scarpi, Emanuela, additional, Cursano, Maria Concetta, additional, Brighi, Nicole, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Basso, Umberto, additional, Fornarini, Giuseppe, additional, Bleve, Sara, additional, Farolfi, Alberto, additional, Altavilla, Amelia, additional, Olmos, David, additional, and Castro, Elena, additional

Published
2023
Full Text
View/download PDF

21. Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

Author

Altavilla, Amelia, primary, Caroli, Paola, additional, Giunta, Emilio Francesco, additional, Scarpi, Emanuela, additional, Rossetti, Virginia, additional, Casadei, Chiara, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Bleve, Sara, additional, Cursano, Maria Concetta, additional, Gasperoni, Lorenzo, additional, Matteucci, Federica, additional, and De Giorgi, Ugo, additional

Published
2023
Full Text
View/download PDF

22. Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

Author

Schepisi, Giuseppe, primary, Gianni, Caterina, additional, Cursano, Maria Concetta, additional, Gallà, Valentina, additional, Menna, Cecilia, additional, Casadei, Chiara, additional, Bleve, Sara, additional, Lolli, Cristian, additional, Martinelli, Giovanni, additional, Rosti, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2023
Full Text
View/download PDF

26. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

Author

Conteduca, Vincenza, Di Tullio, Piergiorgio, Allamprese, Rossana, Bruno, Giuseppina, Lolli, Cristian, Schepisi, Giuseppe, Rosano, Aldo, Giordano, Guido, Garofoli, Marianna, Chiuri, Vincenzo Emanuele, Fratino, Lucia, Zanardi, Elisa, Galli, Luca, Massari, Francesco, Falagario, Ugo, Rescigno, Pasquale, Fornarini, Giuseppe, Sanguedolce, Francesca, Santini, Daniele, Procopio, Giuseppe, Caffo, Orazio, Carrieri, Giuseppe, Landriscina, Matteo, and De Giorgi, Ugo

Abstract

Background: Currently, several therapies are available for metastatic castration-resistant prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first sought the prognostic value of duration on androgen-deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) in patients receiving androgen-receptor-signaling inhibitors (ARSI) for mCRPC. Methods: A multicenter cohort of mCRPC patients who started ARSI between July 2011 and October 2021 was identified. Based on their initial disease burden and duration on ADT for HSPC, primary progressive (PP) men were classified into four groups: low/intermediate-risk localized disease (LOC) and high-risk localized/locally advanced disease (LAD) and short-term (ST) < 24 vs. long-term (LT) ADT ≥ 24 months, whereas de novo (DN) mHSPC were subdivided into short-time vs. long-time to CRPC. Results: We included 919 mCRPC patients with a median age of 77 years [interquartile range (IQR) = 71–82)]. Median ADT duration in HSPC was 24 months (IQR = 14–40). Median follow-up was 91 months (IQR = 62–138), median OS and PFS from ARSI start were 20 (IQR 10–32) and 10 months (IQR = 5–19), respectively. In PP developing metastatic disease (n= 655, 71.3%), LOC and LAD with ST ADT had a greater than almost double-risk of death compared to LT ADT (LOC/ST: hazard ratio [HR] = 2.01; 95% CI 1.54–2.64; LAD/ST: HR = 1.73; 95% CI 1.34–2.24; p< 0.001). In the multivariate analysis including age, prognostic cohort, Gleason, ECOG, radical radiotherapy and prostatectomy, groups with ST ADT were associated with worse OS compared to LT ADT (LOC/ST: HR = 1.84; 95% CI 1.38–2.45; p< 0.001; LAD/ST: HR = 1.59; 95% CI 1.21–2.10; p< 0.001), along with ECOG > 2 (HR = 1.55; 95% CI 1.06–2.26; p= 0.03). There were also similar results of PFS. Moreover, long-time to CRPC in patients with history of DN mHSPC (n= 264, 28.7%) resulted in a better OS/PFS (HR = 0.76, 95% CI 0.56–1.02, p= 0.064 and HR = 0.74, 95% CI 0.55–0.99, p= 0.042, respectively). Conclusions: Our study showed that duration on ADT for mHSPC was significantly associated with survival in mCRPC undergoing ARSI. These findings suggest a possible connection between initial management of prostate tumour and a better prognostication in mCRPC. Prospective trials are warranted.

Published
2024
Full Text
View/download PDF

28. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

Author

Gianni, Caterina, primary, Palleschi, Michela, additional, Schepisi, Giuseppe, additional, Casadei, Chiara, additional, Bleve, Sara, additional, Merloni, Filippo, additional, Sirico, Marianna, additional, Sarti, Samanta, additional, Cecconetto, Lorenzo, additional, Di Menna, Giandomenico, additional, Schettini, Francesco, additional, and De Giorgi, Ugo, additional

Published
2022
Full Text
View/download PDF

31. Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer

Author

Bleve, Sara, primary, Cursano, Maria Concetta, additional, Casadei, Chiara, additional, Schepisi, Giuseppe, additional, Menna, Cecilia, additional, Urbini, Milena, additional, Gianni, Caterina, additional, De Padova, Silvia, additional, Filograna, Alessia, additional, Gallà, Valentina, additional, Rosti, Giovanni, additional, Barone, Domenico, additional, Chovanec, Michal, additional, Mego, Michal, additional, and De Giorgi, Ugo, additional

Published
2022
Full Text
View/download PDF

32. High exosomal PD-L1 expression in relation to lymph node progression in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (abi) or enzalutamide (enza).

Author

Conteduca, Vincenza, primary, Del Re, Marzia, additional, Scarpi, Emanuela, additional, Crucitta, Stefania, additional, Gurioli, Giorgia, additional, Restante, Giuliana, additional, Cucchiara, Federico, additional, Lolli, Cristian, additional, Brighi, Nicole, additional, Schepisi, Giuseppe, additional, Casadei, Chiara, additional, Ulivi, Paola, additional, Beltran, Himisha, additional, Danesi, Romano, additional, and De Giorgi, Ugo, additional

Published
2022
Full Text
View/download PDF

33. Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Author

Conteduca, Vincenza, primary, Casadei, Chiara, additional, Scarpi, Emanuela, additional, Brighi, Nicole, additional, Schepisi, Giuseppe, additional, Lolli, Cristian, additional, Gurioli, Giorgia, additional, Toma, Ilaria, additional, Poti, Giulia, additional, Farolfi, Alberto, additional, and De Giorgi, Ugo, additional

Published
2022
Full Text
View/download PDF

34. Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC).

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Rossi, Alice, additional, Ferroni, Fabio, additional, Gurioli, Giorgia, additional, Bleve, Sara, additional, Gianni, Caterina, additional, Schepisi, Giuseppe, additional, Brighi, Nicole, additional, Lolli, Cristian, additional, Cursano, Maria Concetta, additional, Virga, Alessandra, additional, Casadei, Chiara, additional, Altavilla, Amelia, additional, Farolfi, Alberto, additional, Ulivi, Paola, additional, Barone, Domenico, additional, Matteucci, Federica, additional, Paganelli, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2022
Full Text
View/download PDF

35. Additional file 1 of Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

Author

Gurioli, Giorgia, Conteduca, Vincenza, Brighi, Nicole, Scarpi, Emanuela, Basso, Umberto, Fornarini, Giuseppe, Mosca, Alessandra, Nicodemo, Maurizio, Banna, Giuseppe Luigi, Lolli, Cristian, Schepisi, Giuseppe, Ravaglia, Giorgia, Bondi, Isabella, Ulivi, Paola, and De Giorgi, Ugo

Abstract

Additional file 1: Table S1. Correlation analysis of gene expression biomarkers; we performed an analysis to evaluate the correlation of all the biomarkers considered.

Published
2022
Full Text
View/download PDF

37. Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Caroli, Paola, additional, Lolli, Cristian, additional, Gurioli, Giorgia, additional, Brighi, Nicole, additional, Poti, Giulia, additional, Farolfi, Alberto, additional, Altavilla, Amelia, additional, Schepisi, Giuseppe, additional, Matteucci, Federica, additional, Paganelli, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

39. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration‐resistant cancer patients

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Wetterskog, Daniel, additional, Brighi, Nicole, additional, Ferroni, Fabio, additional, Rossi, Alice, additional, Romanel, Alessandro, additional, Gurioli, Giorgia, additional, Bleve, Sara, additional, Gianni, Caterina, additional, Schepisi, Giuseppe, additional, Lolli, Cristian, additional, Cortesi, Pietro, additional, Matteucci, Federica, additional, Barone, Domenico, additional, Paganelli, Giovanni, additional, Demichelis, Francesca, additional, Beltran, Himisha, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

40. Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Farolfi, Alberto, additional, Brighi, Nicole, additional, Rossi, Lorena, additional, Gurioli, Giorgia, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Bleve, Sara, additional, Gianni, Caterina, additional, Virga, Alessandra, additional, Altavilla, Amelia, additional, Burgio, Salvatore Luca, additional, Menna, Cecilia, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

42. Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC).

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Wetterskog, Daniel, additional, Ferroni, Fabio, additional, Rossi, Alice, additional, Romanel, Alessandro, additional, Gurioli, Giorgia, additional, Bleve, Sara, additional, Gianni, Caterina, additional, Brighi, Nicole, additional, Schepisi, Giuseppe, additional, Lolli, Cristian, additional, Cortesi, Pietro, additional, Barone, Domenico, additional, Demichelis, Francesca, additional, Paganelli, Giovanni, additional, Beltran, Himisha, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

43. Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review

Author

Schepisi, Giuseppe, primary, Gianni, Caterina, additional, Bleve, Sara, additional, De Padova, Silvia, additional, Menna, Cecilia, additional, Lolli, Cristian, additional, Filograna, Alessia, additional, Conteduca, Vincenza, additional, Urbini, Milena, additional, Gallà, Valentina, additional, Casadei, Chiara, additional, Rosti, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

44. Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC).

Author

Conteduca, Vincenza, primary, Scarpi, Emanuela, additional, Wetterskog, Daniel, additional, Caroli, Paola, additional, Romanel, Alessandro, additional, Lolli, Cristian, additional, Jayaram, Anuradha, additional, Gurioli, Giorgia, additional, Brighi, Nicole, additional, Poti, Giulia, additional, Wingate, Anna, additional, Schepisi, Giuseppe, additional, Matteucci, Federica, additional, Paganelli, Giovanni, additional, Demichelis, Francesca, additional, Attard, Gerhardt, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

45. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy

Author

Schepisi, Giuseppe, primary, Casadei, Chiara, additional, Toma, Ilaria, additional, Poti, Giulia, additional, Iaia, Maria Laura, additional, Farolfi, Alberto, additional, Conteduca, Vincenza, additional, Lolli, Cristian, additional, Ravaglia, Giorgia, additional, Brighi, Nicole, additional, Altavilla, Amelia, additional, Martinelli, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

46. Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress

Author

De Padova, Silvia, primary, Urbini, Milena, additional, Schepisi, Giuseppe, additional, Virga, Alessandra, additional, Meggiolaro, Elena, additional, Rossi, Lorena, additional, Fabbri, Francesco, additional, Bertelli, Tatiana, additional, Ulivi, Paola, additional, Ruffilli, Federica, additional, Casadei, Chiara, additional, Gurioli, Giorgia, additional, Rosti, Giovanni, additional, Grassi, Luigi, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

47. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging

Author

Conteduca, Vincenza, primary, Poti, Giulia, additional, Caroli, Paola, additional, Russi, Sabino, additional, Brighi, Nicole, additional, Lolli, Cristian, additional, Schepisi, Giuseppe, additional, Romeo, Antonino, additional, Matteucci, Federica, additional, Paganelli, Giovanni, additional, Marchetti, Paolo, additional, and De Giorgi, Ugo, additional

Published
2021
Full Text
View/download PDF

48. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Author

Conteduca, Vincenza, Jayaram, Anuradha, Romero-Laorden, Nuria, Wetterskog, Daniel, Salvi, Samanta, Gurioli, Giorgia, Scarpi, Emanuela, Castro, Elena, Marin-Aguilera, Mercedes, Lolli, Cristian, Schepisi, Giuseppe, Maugeri, Antonio, Wingate, Anna, Farolfi, Alberto, Casadio, Valentina, Medina, Ana, Puente, Javier, Vidal, Mª José Méndez, Morales-Barrera, Rafael, Villa-Guzmán, Jose C., Hernando, Susana, Rodriguez-Vida, Alejo, González-del-Alba, Aránzazu, Mellado, Begoña, Gonzalez-Billalabeitia, Enrique, Olmos, David, Attard, Gerhardt, and De Giorgi, Ugo

Published
2019
Full Text
View/download PDF

50. Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors

Author

Schepisi, Giuseppe, primary, Conteduca, Vincenza, additional, Casadei, Chiara, additional, Gurioli, Giorgia, additional, Rossi, Lorena, additional, Gallà, Valentina, additional, Cursano, Maria Concetta, additional, Brighi, Nicole, additional, Lolli, Cristian, additional, Menna, Cecilia, additional, Farolfi, Alberto, additional, Burgio, Salvatore Luca, additional, Altavilla, Amelia, additional, Martinelli, Giovanni, additional, and De Giorgi, Ugo, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results